To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - Notification of Major Interest in Mediclinic International plc shares

Release Date: 01/07/2019 16:30
Code(s): MEI     PDF:  
Wrap Text
Notification of Major Interest in Mediclinic International plc shares

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company” or the “Group”)

1 July 2019

Notification of Major Interest in Mediclinic International plc shares

1a. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are at-
tached ii:                                                                              Mediclinic International
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights                                                                    X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify)iii:
3. Details of person subject to the notification obligationiv
Name                                                                          Genesis Investment Management, LLP
City and country of registered office (if applicable)                                 21 Grosvenor Place, London
4. Full name of shareholder(s) (if different from 3.)v
Name                                                                                                         N/A
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or
reached vi:                                                                                       01st July 2019
6. Date on which issuer notified (DD/MM/YYYY):                                                    01st July 2019
7. Total positions of person(s) subject to the notification obligation
                                               % of voting rights
                                               through financial in-
                         % of voting rights    struments                                     Total number of
                         attached to shares    (total of 8.B 1 + 8.B    Total of both in %   voting rights of
                         (total of 8. A)       2)                       (8.A + 8.B)          issuer vii
Resulting situation
on the date on
which threshold
was crossed or
reached                  6.76%                                          6.76%                737,243,810
Position of previ-
ous notification (if
8. Notified details of the resulting situation on the date on which the threshold was crossed or
reached viii
A: Voting rights attached to shares
                       Number of voting rights ix             % of voting rights
                                               Indirect                                       Indirect
Class/type of          Direct                  (Art 10 of Di-           Direct                (Art 10 of Di-
shares                 (Art 9 of Directive     rective                  (Art 9 of Directive   rective
ISIN code (if possi-   2004/109/EC)            2004/109/EC)             2004/109/EC)          2004/109/EC)
ble)                   (DTR5.1)                (DTR5.2.1)               (DTR5.1)              (DTR5.2.1)
GB00B8HX8Z88            49,890,489                                       6.76%
SUBTOTAL 8. A                        49,890,489                                      6.76%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
                                                           Number of voting
                                                           rights that may be ac-
                      Expira-                              quired if the instru-
Type of financial     tion       Exercise/                 ment is                 % of voting
instrument            date x     Conversion Period xi      exercised/converted.    rights
                                 SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive
2004/109/EC (DTR5.3.1.1 (b))
                                 Exercise/        Physical or
Type of finan-    Expiration     Conversion       cash              Number of        % of voting
cial instrument   date x         Period xi        settlement xii    voting rights    rights
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity
and does not control any other undertaking(s) holding directly or indirectly an interest in the (under-
lying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal
entityxiv (please add additional rows as necessary)
                                                           % of voting rights
                           % of voting rights if it        through financial in-          Total of both if it
                           equals or is higher             struments if it equals         equals or is higher
                           than the notifiable             or is higher than the          than the notifiable
Name xv                    threshold                       notifiable threshold           threshold
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
Following an internal restructuring at Genesis Investment Management LLP (“GIM”), all client arrange-
ments transitioned from Genesis Asset Managers, LLP (“GAM”) to GIM with effect from 30 June 2019.
From that date, GIM became the investment manager lawfully managing investments for clients, which has
triggered notifications under DTR5 for both GAM and GIM in relation to their holdings in Mediclinic Interna-
tional plc
Place of completion                                 London, England
Date of completion                                  01st July 2019

About Mediclinic International plc

Mediclinic is an international private healthcare services group, established in South Africa in
1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United
Arab Emirates.

The Group’s core purpose is to enhance the quality of life.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the con-
tinuum of care in such a way that the Group will be regarded as the most respected and trusted
provider of healthcare services by patients, medical practitioners, funders and regulators of
healthcare in each of its markets.

Mediclinic comprises 77 hospitals, five sub-acute hospitals, 12 day case clinics and 21 outpatient
clinics. Hirslanden operates 18 hospitals, two day case clinics and three outpatient clinics in Swit-
zerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operates 52 hospitals, five
sub-acute hospitals and 12 day case clinics with more than 8 500 inpatient beds; and Mediclinic
Middle East operates seven hospitals, two day case clinics and 21 outpatient clinics with more
than 900 inpatient beds in the United Arab Emirates.

The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United Kingdom,
with secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Na-

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare
group based in the United Kingdom and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
+44 (0)20 3786 8181

Media queries
FTI Consulting
Brett Pollard/Debbie Scott – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd

Date: 01/07/2019 04:30:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Email this JSE Sens Item to a Friend.

Share This Story